Chemomab Therapeutics CMMB

Drug Manufacturers - General, Healthcare

$1.03

−4.63%

Market cap: $592.6M
PE: n/m; not a meaningful number
Forward PE: n/m; not a meaningful number
Price to sales: n/m; not a meaningful number
EV/EBIT: n/m; not a meaningful number
Revenue, 12 months: n/m; not a meaningful number
Net margin: n/m; not a meaningful number
Free cash flow yield: n/m; not a meaningful number

Charts

Financials

Income statement for CMMB, by quarter
Income statement	Q2 FY20	Q3 FY20	Q4 FY20	Q1 FY21	Q2 FY21	Q3 FY21	Q4 FY21	Q1 FY22	Q2 FY22	Q3 FY22	Q4 FY22	Q1 FY23
R&D	$847K−67%	$1M−82%	$1.3M+22%	$1.2M−26%	$1.3M+54%	$1.5M+44%	$2.4M+90%	$2.7M+137%	$2.9M+123%	$5.4M+265%	$5.9M+147%	$6.9M+151%
SG&A	$254K−87%	$194K−89%	$688K−47%	$542K+257%	$1.4M+469%	$1.4M+624%	$2.6M+284%	$2.6M+375%	$3.3M+131%	$2.9M+106%	$2.7M+4%	$2.2M−16%
Pre-tax income	n/a	n/a	n/a	n/a	−$2.8M	−$3M	−$5M	−$5.1M	−$6.7M+143%	−$8.1M+172%	−$8.3M+64%	−$8.7M+71%
	n/a	n/a	n/a	n/a	$0	$0	$0	$0	−$544K	$0	$10K	$21K
Net income	−$1.1M−76%	−$1.2M−83%	−$2M−65%	−$1.7M+1%	−$2.8M+156%	−$3M+143%	−$5M+158%	−$5.1M+200%	−$6.2M+124%	−$8.1M+172%	−$8.3M+64%	−$8.8M+72%
	$0.03	$0.04	n/a	$0.04−15%	$0.05+63%	$0.05+44%	−$0.08	$0.09+100%	$0.11+108%	$0.14+169%	−$0.16+100%	$0.16+82%
	32.4M+5496%	34.8M+5912%	n/a	39.2M+21%	54.1M+67%	57M+64%	60.9M	57M+46%	57M+6%	57.2M+0%	56.3M−8%	55.2M−3%

EPS, diluted: 3 periods, Q4 FY19 to Q4 FY22: quarter's net income to common over its shares, to the cent.

Diluted shares: 3 periods, Q4 FY19 to Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Chemomab Therapeutics' size, closest first.

Company	Market cap	PE	Its 10y median PE	P/S	Revenue growth	Net margin
CMMBChemomab Therapeutics	$592.6M	n/m	n/a	n/m	n/m	n/m
ZVRAZevra Therapeutics	$582.6M	10.5×	12.3×	4.3×	+119%	42.8%
CRMDCorMedix	$611.9M	3.7×	4.0×	1.3×	+281%	40.5%
IRWDIronwood Pharmaceuticals	$571.7M	4.5×	14.9×	1.5×	+26%	33.4%
PBYIPuma Biotechnology	$568.9M	21.2×	12.3×	2.5×	−3%	11.6%
ARVNArvinas	$477.3M	45.6×	52.3×	1.5×	−15%	2.9%
COLLCollegium Pharmaceutical	$747.5M	18.5×	19.1×	0.9×	+14%	5.9%
ABUSArbutus Biopharma	$831M	5.4×	5.6×	4.6×	n/m	84.2%
AMPHAmphastar Pharmaceuticals	$1.1B	14.8×	20.6×	1.5×	+1%	10.8%
OMEROmeros	$1.2B	10.9×	11.7×	n/m	n/m	n/m
PCRXPacira BioSciences	$1.5B	104×	65.6×	1.9×	+6%	2.0%
Peer median	$679.7M	12.8×	13.6×	1.5×	+10%	11.6%